Fisher & Paykel Healthcare’s Post

🌍 Today is #WorldBronchiectasisDay! Let's raise awareness about this chronic lung condition affecting millions. At Spero we hope to raise awareness about this chronic lung condition by educating patients and clinicians. Spero is doing the important work of conducting research in this area of unmet need to advance new therapies and show compassion to bronchiectasis patients. Learn more from COPD Foundation: https://bit.ly/3XMCcUP. #WorldBronchiectasisDay2024

Benefits of RAVCARE for Opportunistic Screening in COPD Patients Utilizing RAVCARE Digital Therapeutics for opportunistic screening in COPD patients offers several advantages: Increased Accessibility: RAVCARE makes screening readily available in various settings, overcoming limitations associated with traditional methods. Improved Early Detection: Early identification of COPD allows for timely intervention, potentially slowing disease progression and preventing complications like exacerbations and hospitalizations. Enhanced Patient Engagement: User-friendly interfaces and self-administered tools can empower patients to take an active role in their health management. Cost-Effectiveness: Compared to traditional screening methods, RAVCARE offers a potentially cost-effective solution, especially when considering the long-term cost savings associated with early intervention. Data-Driven Insights: The data collected through RAVCARE can provide valuable insights into COPD prevalence and risk factors within specific populations. This information can be used to inform targeted screening programs and public health initiatives. Learn more at https://lnkd.in/eCVFFjTN #copd #digitaltherapeutics #populationhealth

Today we recognize the estimated 400 million people globally living with a rare disease. We know there is much work ahead to address unmet medical needs of these patients and that means securing a timely diagnosis, effectively treating their symptoms, but also improving their lives as a whole. So important that innovations emerge to help people with rare diseases live better, enabling greater autonomy and more quality time with the people they love, doing activities that bring them joy.   Many patients with rare, chronic and complex diseases such as primary immunodeficiencies depend on plasma-derived therapies, requiring frequent and life-long treatment. With therapeutic advances such as subcutaneous immunoglobulin treatment, those patients now have the option to self-administer at home, which can already contribute substantially to improving their lives. We need to continue investing as an industry to shorten infusion time and ease overall burden of IG administration, whilst developing more holistic digital solutions that help patients better manage their disease and treatment.   This #RareDiseaseDay, it’s important for the healthcare ecosystem to consider the whole patient, focusing both on transformative therapies to change the treatment paradigm for the future, but also meeting patients where they are today with innovations to improve their treatment experience.   #RareDiseaseDay #Plasma #PlasmaDerivedTherapies #Innovation 

Treating #BloodCancer requires an individualized approach that includes complementary and combinable therapies. We’re committed to developing innovative treatment options to help unlock transformational outcomes for patients by collaborating with the healthcare community, including patients. We’re dedicated to advancing our collective understanding of these diseases. That’s why at #ASH23 we are presenting new data from our differentiated portfolio, to help address the needs across multiple myeloma and B-cell malignancies. https://bit.ly/46ZnISI #MultipleMyeloma

Grifols is honored to celebrate #Alpha1AwarenessMonth and #COPDAwarenessMonth. It is estimated that 90% of patients with alpha-1 are undiagnosed. AlphaID screening kits make it easy to rule out alpha-1 as a predisposition to a COPD diagnosis. HCPs can order fast, free, and accurate screening kits at https://lnkd.in/d3fFz5Gd. For those with COPD, test kits may now be ordered at https://lnkd.in/efc9Rcaj The receipt of this free testing service does not create any expectation or obligation to purchase or use any product or service offered by any manufacturer. #COPDSmokeScreen #Alpha1Awareness #geneticcopd  #alpha1screening #alphaidathome

VIDA's AI-driven mucus plug analysis will be featured in 5 #ATS2024 abstracts. In this analysis of #SARP patients by Peterson et al., a regional association between mucus plugging and downstream air trapping was evident in subjects with severe plugs. These results add to the growing evidence that plugs could be targeted with therapies to improve downstream air trapping in patients with asthma. https://hubs.ly/Q02wxnyz0 Meet with VIDA at ATS: https://hubs.ly/Q02wxrxs0 #mucusplugs #mucusplugging #asthma #digitalbiomarkers

Supporting you so you can support your patients. The Galleri test only requires a simple blood draw, allowing integration into existing patient touchpoints such as annual health checks or routine blood work. Learn more about how we can help: https://bit.ly/3uQmwDO See Important Safety Information at https://bit.ly/45FRUlI #MCED #MultiCancerEarlyDetection #CancerScreening #DetectCancerEarly The Galleri test should be used in addition to healthcare provider recommended screening tests. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

🌟 At AstraZeneca , we're not just advancing medicine; we're transforming lives. By integrating #AI with home spirometry, we aim to bring early diagnosis and monitoring of respiratory diseases right to your doorstep. It's innovation with purpose.💡 #RespiratoryHealth #AIInnovation

𝗢𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗶𝘀 𝗻𝗼𝘄 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝗳𝗼𝗿 𝗿𝗲𝗽𝗹𝗮𝘆! 👉 Access the webinar recording here: https://lnkd.in/eF63HsBb In this webinar, the following topics were explored: ➢ CONVINCE Study design and pivotal findings: comparing high-dose hemodiafiltration with standard hemodialysis ➢ Impact on patient care and treatment strategies ➢ Implications for future research and study design Don't miss the chance to catch up on this insightful conversation, gain valuable insights, and expand your knowledge about advancements in kidney disease research. #KidneyDisease #KidneyHealth #CKD #Dialysis #ClinicalTrials #MedicalResearch

Grifols is honored to celebrate #Alpha1AwarenessMonth and #COPDAwarenessMonth. It is estimated that 90% of patients with alpha-1 are undiagnosed. AlphaID screening kits make it easy to rule out alpha-1 as a predisposition to a COPD diagnosis.   HCPs can order fast, free, and accurate screening kits at https://lnkd.in/eczDhHez. For those with COPD, test kits may now be ordered at https://lnkd.in/e9M4XwxM   The receipt of this free testing service does not create any expectation or obligation to purchase or use any product or service offered by any manufacturer.   #COPDSmokeScreen #Alpha1Awareness #geneticcopd  #alpha1screening #alphaidathome